NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT02059850 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it was withdrawn. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide in Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma and 3 more conditions. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 31 Jul 2014 and a primary completion date of 31 Jan 2016. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02059850 |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Enrollment | 0 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma |
| Drugs | Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide |
| Start | 31 Jul 2014 |
| Primary completion | 31 Jan 2016 |
| Study completion | 31 Jan 2016 |
| Last update posted | 3 Feb 2016 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Seth Pollack
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fred Hutchinson Cancer Research Center/university of Washington Cancer Consortium
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02059850
Each answer restates registry values shown on this page.
What is NCT02059850?
NCT02059850 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide in Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma and 3 more conditions.
Who leads NCT02059850?
The registry names Seth Pollack (principal investigator, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) as the overall official.
Where does NCT02059850 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02059850 study?
The registered drug and biological interventions are Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide.
When did NCT02059850 end?
The registry lists a primary completion date of 31 Jan 2016 and a study completion date of 31 Jan 2016. The sponsor last updated the record on 3 Feb 2016.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.